Vol 17, No 3 (2017)

MRMC 17-3

Table of Contents


Development of a predictive pharmacophore model and a 3D-QSAR study for an in silico screening of new potent Bcr-Abl kinase inhibitors
Dr. Alan Talevi
Therapy of Chronic Hepatitis C in the Era of Nanotechnology and Interferon/Ribavirin-free regimes: New Global Challenges
Dr. María Luján Cuestas
Searching for novel Janus kinase-2 inhibitors using a combination of pharmacophore modeling, 3D QSAR studies and virtual screening
Dr. Eleni Vrontaki, Dr. Georgia Melagraki, Antreas Afantitis, Thomas Mavromoustakos, George Kolliasc
LHRH-Targeted Drug Delivery Systems for Cancer Therapy
Dr. Alan Talevi
Current State and Future Perspectives in QSAR Models to Predict Blood Brain Barrier penetration in Central Nervous System Drug R&D
Dr. Alan Talevi
Nanotechnology as potential strategy for the treatment of pharmacoresistant epilepsy and comorbid psychiatric disorders
Dr. Alan Talevi
Nanostructured systems for the organelle-specific delivery of anticancer drugs
Dr. Alan Talevi
Dr. Alan Talevi
Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy
Dr. Alan Talevi
Alzheimer’s Drug Discovery Maze: A snap view of the past decade’s diverse pharmacological targets for the disorder.
Dr. Donald Sikazwe, Dr. Raghunandan Yendapally, Dr. Sushma Ramsinghani, Mr. Malik Khan

ISSN: 1875-5607